Mithra Announces Commercial Launch of Myring™ in Germany, the biggest market in Europe

/in , /by

Successful launch of Mithra’s hormonal contraceptive ring in Germany under the trademark MYCIRQ® Germany is the largest European market and the second worldwide, with 3 million vaginal rings sold per year Mithra CDMO pursues the manufacturing of its Myring™ orders in compliance with all the measures required by the Belgian authorities Liege, Belgium, 2 April […]

Read more →

Mithra Announces Donesta® Phase III Clinical Program Update

/in , /by

Liege, Belgium, 01 April 2020 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces an update on the Donesta® Phase III Clinical Program called “E4 Comfort”, which aims at enrolling approximately 2200 menopausal women (40-65 years) and includes two pivotal studies: in North America (United States/Canada) launched in […]

Read more →

Mithra Reports Full Year 2019 Financial Results

/in , /by

Record revenue (EUR 96.5 million) and EBITDA (EUR 40.7 million) increased respectively by 47% and 6%, mainly driven by U.S. deal for Estelle® Anticipated future licensing milestones for Estelle® of EUR 322 million (out of a total of EUR 486 million) Net loss significantly reduced to EUR 26.6 million (EUR 89.7 million in June 2019) thanks […]

Read more →

Mithra to Host Webcast for Announcement 2019 Financial Results on 9 March 2020

/in , /by

Liege, Belgium, 05 March 2020 – 17:45  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it will host a live webcast on Monday 9 March 2020 at 15:00 CET/ 09:00 EST to announce its 2019 financial and operating results.

Read more →

Mithra Receives acceptance of Marketing Authorization Application (MAA) to market Estelle® in Belgium and Luxembourg

/in , /by

Liege, Belgium, 03 March 2020 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that the European Medicines Agency (EMA) has accepted its regulatory submission to market Estelle® in Belgium and Luxembourg.  Estelle® is Mithra’s novel combined oral contraceptive (COC) product candidate, containing 15 mg Estetrol (E4) and 3 […]

Read more →

EMA Accepts Richter’s Marketing Authorization Application (MAA) for Estelle®, a Novel Combined Oral Contraceptive

/in , /by

Liege, Belgium, 27 February 2020 – 17:45  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announced that the European Medicines Agency (EMA) has accepted Gedeon Richter’s (hereinafter: “Richter”) regulatory submission for Estelle®, a combined oral contraceptive containing estetrol (E4) and drospirenone. Developed by Mithra, the product candidate is composed of […]

Read more →

Mithra Announces Commercial Launch of Myring™ in Belgium

/in , /by

Mithra’s hormonal contraceptive ring is now available in pharmacies in Belgium under the trademark name Myloop® Large-scaled global commercialization of Myring™, especially in the world’s three largest markets Mithra CDMO in Belgium expected to produce nearly 2 million rings in 2020 Liege, Belgium, 12 February 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a […]

Read more →

Mithra receives positive ruling on Patent Income Deduction

/in , /by

Liege, Belgium, 10 February 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has received a positive ruling from the Belgian tax authorities, enabling Mithra to benefit from the Belgian Patent Income Deduction (PID) 1 on patent related income arising from Mithra’s E4-based products (Estelle®, […]

Read more →

Statement from the CEO and the Board of Directors of Mithra following the articles published in the Belgian press

/in , /by

Liege, Belgium, 23 January 2020 – Following publications in the press on Wednesday, 22 January 2020 regarding an alleged insider trading offence attributed to Mr. François Fornieri, CEO of Mithra Pharmaceuticals, Mr. Fornieri vigorously contests any involvement in any such offence and deeply regrets the prejudice caused by this alleged information to Mithra (Euronext Brussels: […]

Read more →

Mithra Signs LSA for Commercialization of Myring™ in Italy, the Third Biggest Worldwide Market

/in , /by

Mithra grants a license to Farmitalia for commercialization of its vaginal contraceptive ring in Italy Italy is the third largest worldwide contraceptive ring market with nearly 2 million vaginal rings sold per year Mithra CDMO will launch the production of nearly 20,000 rings per month for the Italian market in the coming weeks Liege, Belgium, […]

Read more →